Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

PCSK9 Inhibitors: Bloodwork Guide

Recommended lab tests and biomarkers to monitor before, during, and after PCSK9 Inhibitors therapy. Testing schedules are based on clinical protocols and published monitoring guidelines.

Back to PCSK9 Inhibitors overview

Before Starting (1 test)

Biomarker Expected Effect Retest
ALT/AST → normalizes Every 12 weeks

During Treatment (3 tests)

Biomarker Expected Effect Retest
LDL Cholesterol ↓ decreases Every 8 weeks
Total Cholesterol ↓ decreases Every 12 weeks
Lipoprotein(a) ↓ decreases Every 12 weeks